

**Oregon Prescription Drug Monitoring Program Advisory Commission**

**July 21, 2017 Meeting Minutes**

1:00 PM to 3:00 PM

Portland State Office Building

800 NE Oregon Street, **Room 918**

Portland, OR 97232

**ATTENDEES:**

**Advisory Commission Present:** Chris Apgar, John McIlveen, Clare Midson, Michael Millard, Chris Sorvari

**By Telephone:** Sara Love, Carrie Schriebman, Tyler Swift,

**Advisory Commission Absent:** Bill Jordan, Sharon Meieran, Laura Scobie, Matthe Eschelbach

**OHA Staff:** Tamara Ramirez, Drew Simpson, Josh Van Otterloo, Stephanie Vesik

**Guests:** Karissa Dunkley and Dennis McNannay from Curadite

Decisions
1. The meeting minutes from January 2016 were approved as written.

**INTRODUCTIONS**

Technical issues delayed the start of the meeting while the phone line was fixed. PDMP team committed to testing the system prior to the meeting next time.

Apgar called the meeting to order. Attendees introduced themselves in the order they were seated at the table and then those on the phone.

**STANDING AGENDA ITEMS**

**a. Review Quarterly Metrics**

Simpson presented highlights from the 2017 2nd quarter (Q2) report. He noted overall prescribing is going down. Compared to 2016 in the same timeframe, the number of prescriptions for controlled substances decreased by 11%. The biggest change in active users continues to be delegates, who as a group increased by 45% since 2016 Q2. Utilization of the PDMP is up 13% across all user types from 2016 Q2. Simpson also noted that the percent of top prescribers enrolled in the PDMP has remained stagnate at approx. 75%.

Vesik presented the April - June 2017 Pharmacy Compliance Report. Vesik reported continued efforts to clean up enrollment lists and remove long dormant accounts.

**b. Research study updates**

Van Otterloo reported a DUA was denied for a PhD researcher from SC who was unable to fill the required aspects of the DUA.

Van Otterloo also lead discussion around needed improvements to the PDMP's administrative rule to make the requirement for DUAs more explicit for non-research groups requesting data. Millard considers the rule sufficient since the PDMP data is not a public record. Apgar suggested the rule be amended to better clarify disclosures to non-research groups.

**c. Legislative Updates**

HB 4124 – Contract with Appriss has been executed and the project is now in the integration phase. Multiple HIT providers are working with Appriss. A soft launch is underway with three entities. A big push will take place during the fall of 2017.

HB 3440 – This is a new bill that just passed during the 2017 legislative session. A work plan is currently being developed. The relevant aspects of the bill that impact the PDMP include Naloxone prescribing along with the phone number of the individual filling the prescription will be maintained in PDMP database; pharmaceutical and medical directors will have access to PDMP to improve their facilities prescribing practice, licensing boards will send licensing data to determine if licensees meet the PDMP qualification to access the PDMP and interstate data sharing will now be allowed with other states who are able to protect Oregon PDMP data as require by the Oregon PDMP statute. HB 3440 also creates a subcommittee to review PDMP data and determine which prescribers it is recommended receive additional training or education. As discussed during the meeting, the PDMP will work with licensing boards and will not be interacting with prescribers directly.

**3440 Discussion**

At least annually the subcommittee will review and identify prescribers who should receive additional education and training. PDMP staff will prepare the lists and send them to the respective boards so that the boards can provide the training and education that is appropriate.

Simpson will work with Millard to determine how to assemble the subcommittee and reach out to the licensing boards. At October 2017 Advisory Commission meeting a draft process for how the committee will function will be presented and discussed. No subcommittee meetings will be scheduled in 2017. Millard and the PDMP team will meet once between this meeting and the October Advisory Commission meeting.

**OLD BUSINESS**

DEA Lawsuit – Apgar gave an update. The ACLU did not have standing to push the case forward. This means the previous practice requiring a court order prior to the disclosure of PDMP data has been overturned and the DEA can now submit administrative subpoenas instead. Vesik commented that the PDMP will continue to send all request to DOJ for review before disclosing any PDMP data until a formal process has been developed and implemented.

## **NEW BUSINESS**

### **A. Drug take back –**

Karissa Dunkley and Dennis McNannay presented information about a new product that could be used in connection with drug take backs. This was connected to a bill from the 2017 legislative session that did not make it out of committee. There are no current or near future impacts to the PDMP.

### **B. Migration to New PDMP Platform**

The PDMP will be migrating from RxSentry to PDMP AWA<sup>R</sup>x<sup>E</sup> in Oct 2017. This will result in two days down time for the PDMP system and a temporary two week gap in information availability in the PDMP.

## **OPEN ISSUES**

No open issues discussed.

## **PUBLIC COMMENT**

None received.

## **MEMBER WRAP UP**

## **NEXT MEETING DATE**

The next Advisory Commission meeting is scheduled for October 20, 2017 in the PSOB in Room 918 at 1 pm.

## **ADJOURNMENT**

The meeting adjourned at 2:57 PM.